Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Historic EBITDA Margin for Contineum Therapeutics (CTNM) over the last 1 years, with Q2 2023 value amounting to 83.02%.

  • Contineum Therapeutics' EBITDA Margin changed N/A to 83.02% in Q2 2023 from the same period last year, while for Mar 2024 it was 38.16%, marking a year-over-year change of. This contributed to the annual value of 45.81% for FY2023, which is N/A changed from last year.
  • Latest data reveals that Contineum Therapeutics reported EBITDA Margin of 83.02% as of Q2 2023.
  • In the past 5 years, Contineum Therapeutics' EBITDA Margin ranged from a high of 5170.65% in Q1 2023 and a low of 83.02% during Q2 2023